AbbVie vs Canon: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Canon was founded in 1937 by Takeshi Mitarai, Goro Yoshida, Saburo Uchida and is led by Fujio Mitarai.
Company facts
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
Canon
Takeshi Mitarai
Takeshi Mitarai supported the camera laboratory that Goro Yoshida, Saburo Uchida and Takeo Maeda opened in 1933, and became president of its successor, Precision Optical Industry, Co., Ltd., in 1942.
Goro Yoshida
Yoshida took apart a Leica Model II and, as he later recalled, was angered to find it was built from brass, aluminium, iron and rubber yet sold for 420 yen.
Saburo Uchida
Saburo Uchida (1899-1982) co-founded the Precision Optical Instruments Laboratory with Goro Yoshida, his brother-in-law, and Takeo Maeda in November 1933.
Takeo Maeda
Takeo Maeda (1909-1977) was the youngest of the founding group. A former subordinate of Saburo Uchida, he joined Uchida and Goro Yoshida in opening the Precision Optical Instruments Laboratory in Roppongi in November 1933 and worked on the Kwanon prototype and…
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
Canon
- Takeshi Mitarai1942–1974
President
An obstetrician who backed the 1933 camera laboratory, he became president of Precision Optical Industry in 1942 and led the company as it became Canon Camera Co. in 1947, listed in Tokyo in 1949 and opened sales offices in New York and Geneva in the 1950s.
Source - Ryuzaburo Kaku1977–1989
President, later Chairman
As President, he aggressively challenged Xerox's monopoly in the copier market by introducing affordable, personal laser printers and copiers.
Source - Fujio Mitarai1995–present
Chairman and Chief Executive Officer
Born in 1935 and a nephew of Takeshi Mitarai, he joined Canon in 1961, ran Canon U.S.A. as president from 1979 to 1989 and became president of Canon Inc. in 1995.
Source - Tsuneji Uchida2006–2012
President and Chief Operating Officer
During his tenure as President, he maintained strong profitability through strict cost-cutting measures despite the brutal collapse of the digital compact camera market.
Source - Masaya Maeda2016–2020
President and Chief Operating Officer
He led the Image Communication Products group during the height of the DSLR era, cementing Canon's position as the global market leader in interchangeable lens cameras.
Source - Kazuto Ogawa2026–present
President and Chief Operating Officer
Joined Canon in 1981 and led Canon Singapore (2005), Canon Canada (2008) and Canon U.S.A. as President and COO (2018).
Source
Timeline: AbbVie and Canon side by side
1933Canon
Precision Optical Instruments Laboratory opens
Goro Yoshida, Saburo Uchida and Takeo Maeda open a camera laboratory in a Roppongi apartment in Tokyo to build a Japanese 35mm camera that could rival the Leica.
1934Canon
Kwanon prototype
Yoshida builds the Kwanon, Japan's first 35mm focal-plane-shutter camera prototype, named after the Buddhist goddess of mercy. It never goes on sale.
1936Canon
Hansa Canon goes on sale
The lab's first commercial camera, the Hansa Canon, uses a Nikkor lens and rangefinder supplied by Nippon Kogaku, the predecessor of Nikon. The 'Canon' trademark had been filed in 1935.
1937Canon
Precision Optical Industry incorporated
The business is incorporated on August 10, 1937 as Precision Optical Industry, Co., Ltd. Takeshi Mitarai becomes president in 1942.
1949Canon
Tokyo Stock Exchange listing
Canon Camera Co. (renamed in 1947) lists on the Tokyo Stock Exchange when postwar trading resumes, and opens a New York branch in 1955.
1964Canon
Canola 130 calculator
Canon moves beyond cameras with the Canola 130 desktop electronic calculator, followed in 1970 by Japan's first plain-paper copier, the NP-1100, and its first semiconductor lithography tool, the PPC-1.
1969Canon
Renamed Canon Inc.
Canon Camera Co. changes its name to Canon Inc. to reflect a product range that now spans business machines as well as cameras.
1987Canon
EOS system launches
Canon launches the EOS 650 and the all-electronic EF lens mount, the base of its autofocus SLR and later digital SLR lines.
1995Canon
Fujio Mitarai becomes president
Fujio Mitarai takes over as president, exits personal computers and other loss-making lines, and in 1996 starts the Excellent Global Corporation Plan.
2003Canon
Start of No. 1 camera share run
Canon takes the No. 1 share of the global interchangeable-lens digital camera market, a position it has held every year through 2025.
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2016Canon
Toshiba Medical acquisition
Canon completes the ¥665.5 billion (about $5.9 billion) purchase of Toshiba Medical Systems in December 2016, later renamed Canon Medical Systems.
2018Canon
EOS R mirrorless system
Canon launches the full-frame EOS R mirrorless system and RF lens mount.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2023Canon
Nanoimprint lithography launch
Canon releases the FPA-1200NZ2C nanoimprint lithography system in October 2023, able to pattern 14 nm lines, and delists its ADRs from the New York Stock Exchange in March.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2024Canon
First NIL shipment and medical impairment
Canon ships its first nanoimprint system to the Texas Institute for Electronics on September 26, 2024, and books a ~$1.11 billion (¥165.1 billion) goodwill impairment on its medical business for the year.
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025Canon
Record net sales of ~$31 billion (¥4,624.7 billion)
Canon reports record 2025 net sales of ~$31 billion (¥4,624.7 billion) and net income attributable to Canon Inc. of ~$2.23 billion (¥332.1 billion).
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
2026Canon
Phase VII plan and new president
Canon unveils its 2026-2030 Phase VII plan, merges Canon Medical's operations into Canon Inc. on April 1, and appoints Kazuto Ogawa President and COO on March 27 while Fujio Mitarai stays Chairman and CEO.
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
Canon
- Canon Electronics (minority shares)2026Undisclosed
- Redlen Technologies2021$335M
- BriefCam2018Undisclosed
- Kite2017Undisclosed
- Toshiba Medical Systems2016$5.9B
- Axis Communications2015$2.8B
Questions about AbbVie vs Canon
Who is the CEO of AbbVie Inc. and Canon Inc.?
AbbVie Inc. is led by Robert A. Michael and Canon Inc. is led by Fujio Mitarai. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs Canon Inc.?
Canon Inc. was founded in 1937 — 76 years before AbbVie Inc., which was founded in 2013. Canon Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to Canon Inc.?
AbbVie Inc. employs approximately 57,000 people, while Canon Inc. employs approximately 165,547. Canon Inc. has the larger workforce at 165,547 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and Canon Inc. headquartered?
AbbVie Inc. is headquartered in United States and Canon Inc. is headquartered in Japan. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AbbVie Inc. and Canon Inc.?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Canon Inc. was founded by Takeshi Mitarai, Goro Yoshida, Saburo Uchida, Takeo Maeda.
Which company has a longer operating history — AbbVie Inc. or Canon Inc.?
Canon Inc. has been operating for approximately 89 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Canon overview